4D Molecular Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Filed September 28, 2026, the report announces initial enrollment at multiple sites in the 4SIGHT Phase 3 trial of 4D-150 for treatment-naïve patients with diabetic macular edema (DME), and reports two-year SPECTRA trial results. This is a clinical-development update, not a financial-results filing.
Financial and operating metrics
The filing provides no revenue, profit, cash flow, margins, debt, liquidity, or other financial results.
Trial update and comparison
- 4SIGHT: Global, randomized, double-masked Phase 3 trial comparing intravitreal 4D-150 with aflibercept 2 mg in 514 patients. Participants receive five aflibercept loading doses; randomization follows a response assessment after the first three doses. The primary endpoint is non-inferiority in mean change in best-corrected visual acuity (BCVA) at Week 52. Key secondary endpoints include injection burden and the proportion achieving at least a two-step ETDRS-DRSS improvement. Supplemental aflibercept injections are permitted in both arms.
- Regulatory pathway: 4D-150 has FDA Regenerative Medicine Advanced Therapy designation. The company reports alignment with FDA and EMA on the possibility of using the single 4SIGHT trial to support U.S. and European applications, based on existing SPECTRA and PRISM data and the 4FRONT wet AMD Phase 3 program.
- SPECTRA two-year results: Data cutoff was March 12, 2026. Among 22 participants, the company reported no intraocular inflammation, ocular serious adverse events, or specified serious ocular complications, and no progression to proliferative diabetic retinopathy or vitreous hemorrhage.
- Clinical activity: In the Phase 3 dose group (3E10 vg/eye; n=9), mean BCVA gain was 10.8 letters and mean central subfield thickness reduction was 176 μm. After three aflibercept loading doses, the company reported a 61% treatment-burden reduction based on 5.2 mean supplemental injections per patient versus 13.0 projected for on-label aflibercept 2 mg every eight weeks. A 75% reduction (3.2 versus 13.0 injections) was a retrospective estimate using 4SIGHT criteria; the filing cautions actual 4SIGHT results may differ. Two of nine participants remained injection-free.
Outlook, risks, and items to verify
The filing’s development and regulatory statements are forward-looking and subject to clinical, regulatory, and other risks. The company refers investors to the Risk Factors in its most recent Form 10-Q, filed August 13, 2026, and subsequent SEC filings. It disclaims an obligation to update forward-looking statements.
- Verify 4SIGHT enrollment progress, trial execution, and Week 52 results, including visual acuity and injection-burden outcomes.
- Assess whether the small SPECTRA dose-group findings (n=9) are reproduced in larger studies and whether the reported safety profile persists.
- Distinguish the observed 61% SPECTRA treatment-burden reduction from the retrospective 75% estimate; neither establishes 4SIGHT outcomes.
- Monitor regulatory feedback and whether one Phase 3 DME trial is ultimately sufficient to support applications.